Compounded GLP-1 Medications and the FDA's April 30, 2026 Proposal: What Every Prospective Patient Needs to Know Before Enrolling This section carries different regulatory weight than most parts of a telehealth review, and it's worth reading carefully
Pingault JB, O'Reilly PF, Schoeler T, Ploubidis GB, Rijsdijk F, Dudbridge F
Novo Nordisk has launched two large Phase III trials (EVOKE and EVOKE+) to assess whether semaglutide can slow cognitive decline in participants with early-stage Alzheimers disease
Boess, F
Key takeaways MeAgain is the GLP-1 shot tracker app where shot day stays inside the rest of the routine: shot timing, dose history, injection sites, side effects, food, water, weight, progress photos, medication-level context, and Journey Cards on one timeline
Wegovy scripts were essentially flat quarter-to-quarter, even as supply was raised